Objectives: We investigated the patency rates of no-touch saphenous vein grafts anastomosed to the left anterior descending artery compared with the left internal thoracic artery. Further, we compared the patency of no-touch vein grafts to the left anterior descending artery with the patency of no-touch vein grafts to other coronary arteries.
Perspective
The NT SVG harvesting technique was demonstrated to be an effective approach in prevention of late vein graft failure. The NT SVG should be included in the arsenal of conduits in CABG.
See Editorial Commentary page 467.
See Editorial page 455.
Ischemic heart disease is currently the leading cause of death globally and is expected to account for 14.2% of all deaths by 2030. 1 Coronary artery bypass grafting (CABG) is among the most common operations performed in the world 2 and is the best treatment for advanced ischemic heart disease. [3] [4] [5] Graft patency in CABG is a major determinant of clinical prognosis, measured by reoperation rates and long-term survival. 6 The decision on what conduit to use to bypass the left anterior descending (LAD) artery is a settled issue. 3, 4, 7 Since the definitive article by Loop artery (LITA) to bypass the LAD to capture the benefits of greater patency than achieved with conventional saphenous vein grafts (SVGs), and thus improve survival. Since the LITA as a conduit choice for the LAD was made a quality issue by the Society of Thoracic Surgeons, LITA use in the United States has increased, from 87.7% in 2000 to 94.7% in 2009. 9 However, given that CABG is a common operation, the 5.3% of patients who do not receive a LITA are a large number of patients.
There is still discussion about the best choice of conduit for the LAD when a LITA is injured during harvesting or when a surgeon wants to avoid LITA harvesting because of severe frailty, obesity, chronic obstructive pulmonary disease (COPD), intermediate LAD stenosis, or other reasons that place the patient in a particularly high-risk category. In these situations, multiple other conduits are available, such as the radial artery or the right internal thoracic artery, yet none are ideal, and their use sometimes presents difficult technical challenges.
An improved saphenous vein conduit might simplify a complex CABG procedure and would be valuable if the patency was similar to that of the LITA. A conventional harvest causes severe saphenous vein trauma. When SVGs are stripped from the surrounding tissue, spasm is induced, which is overcome by dilatation with normal saline or blood. Mechanical dilatation and suboptimal preservation solution cause vessel wall damage 10 and may explain the higher incidence of early graft occlusion, progressive intimal hyperplasia, atherosclerosis, and late graft occlusion seen in conventional SVGs. 11 Since the beginning of the 1990s, we have been using a technique for SVG preparation whereby the vein is harvested with a pedicle of surrounding tissue intact and no dilatation is used, called the ''no-touch [NT] technique'' (Video 1). 12 This technique provides a superior patency rate, [13] [14] [15] preserved left ventricular function, 16 and a better clinical outcome 17 compared with conventional harvesting, in both the short and the long term. Above all, in a previous study by our group, the NT SVG patency to non-LAD targets was comparable to that of LITA to LAD at a mean time of 16 years postoperatively. 15 With this experience, it seemed reasonable to assume that the NT SVG would achieve an equal, if not greater, patency rate if anastomosed to the LAD.
The primary aim of the present study was to document the patency rates and clinical outcomes in patients with NT SVGs placed to the LAD at a mean of 6 years postoperatively. The secondary aim was to compare the patency of the NT vein grafts placed to the LAD with that of NT vein grafts placed to non-LAD territories.
MATERIALS AND METHODS Study Design
In this observational cohort study, 18 2635 consecutive patients who had undergone CABG between 2003 and 2008 were screened for eligibility. A total of 168 patients were consecutively identified as having received an SVG to the LAD ( Figure 1 ) and having been operated at the Department of Cardiothoracic and Vascular Surgery, € Orebro University Hospital, € Orebro, Sweden. Our local registry and patient files were used to identify this group. Baseline data were retrieved retrospectively from our local registry. The follow-up was performed at a mean of 6 years postoperatively. The study was approved by the Regional Ethical Review Board in Uppsala. Patients were included at follow-up after informed consent had been obtained.
All surviving patients who had received an NT SVG, as a single or a sequential graft, to the LAD were offered a clinical assessment and a computed tomography angiography (CTA). Exclusion criteria were allergy to contrast media, impaired renal function, or inability to participate in the study according to protocol. A total of 97 patients were enrolled in the VIDEO study, and 91 of them underwent 1 CTA. For those who had died before the follow-up, the causes of death were established from the Swedish death registry and patient files.
Clinical Evaluation
The clinical evaluation included history, physical examination, and blood works (complete blood count, renal function, and lipid profile).
Angiography
CTA was selected because of the less-invasive nature of this technique and its reliability in identifying graft occlusion. 19 The electrocardiogramgated CTA examinations were performed with a SOMATOM Flash, dual-source computed tomography scanner (Siemens, Erlangen, Germany). All subjects received 0.25 mg nitroglycerin sublingually, and those with a heart frequency of more than 70 beats/min and no contraindications also were given up to 10 mg metoprolol intravenously before the examination. Sixty to 70 mL of contrast media (Iomeron 400 mg/mL; Bracco, Milan, Italy) was administered with a pressure injector at a flow rate of 6 mL/s, followed by a bolus of 60 mL saline.
The images were reviewed at a Siemens Syngo Multi-Modality Workplace workstation. All images were reviewed by a thoracic radiologist. When possible, the studies were compared with reports and images from previous coronary angiographies. A graft was judged as occluded when it was not opacified by contrast media. The origin of occluded grafts was readily visible in the anterior ascending aorta. The native coronary arteries were not evaluated.
Statistical Methods
Statistical analysis was performed on data from 97 patients, 91 of whom were available for angiographic analysis. These 91 patients had 163 grafts with 286 distal anastomoses, which means that each patient constitutes a cluster of statistically dependent observations regarding patency for anastomoses to the LAD and non-LAD targets. For this reason, the analysis of patency at the level of distal anastomoses had to include adjustments for intrapatient correlations to obtain statistical validity in estimates and confidence intervals (CIs). Therefore, the model was a generalized linear latent and mixed model 20 for binomial data (with 2 possible outcomes, ''yes'' or ''no,'' for patency) with an identity link function. With the identity link function, estimates of the difference in percentage of patency between LAD and non-LAD anastomoses can be directly inferred from the results of the analysis. For calculation of CIs and P values, the intrapatient correlation, with 2 to 6 anastomoses per patient, was accounted for in the model by treating patients as separate clusters and applying cluster-specific formulas for CIs and P values. The model included, in addition to the factor LAD versus non-LAD anastomoses, a temporal component, that is, time from the date of surgery to the date of angiographic assessment, expressed in years. Comparisons of basic patient characteristics were performed using chi-square tests for categoric data and t tests for continuous data. All other CIs and P values are from the generalized linear latent and mixed model. STATA release 14 (StataCorp LP, College Station, Tex; www.stata.com) and SPSS version 22 (SPSS Inc, Chicago, Ill) were used in the computations.
Patency comparisons between NT SVGs to LAD and NT SVGs with non-LAD targets were done with the aim of assessing noninferiority and equivalence of the NT technique for these 2 kinds of anastomoses. The approach recommended by Fleming 21 and Christensen 22 was used. Results are shown as CIs for the differences in patency rates between the investigated anastomoses. The margins of equivalence and noninferiority were set to AE10 percentage points. Through these CIs, possible equivalences between the patency of LAD and the different non-LAD anastomoses can be visualized. CIs that fall completely within the margins of equivalence show no rejection of the equivalence hypothesis; CIs that include zero, but extend outside the margins of equivalence are inconclusive (because of low statistical power for a small dataset), and CIs that do not include zero reject the equivalence hypothesis. The confidence level was set to 90%; therefore, equivalence is evaluated at this level and noninferiority can be deduced from the lower 90% CI level, referred to as 1-sided 95% CI for noninferiority.
RESULTS
A total of 2635 patients underwent CABG between 2003 and 2008 and were examined for eligibility. A total of 168 patients (168/2635; 6.3%) received an SVG to the LAD. Of these, 126 (126/2635; 4.8%) received a planned SVG to the LAD. In the remaining 42 patients (42/2635; 1.6%), the LITA was damaged during harvesting, had low free flow rates, or was too short to reach the LAD and was consequently anastomosed to non-LAD targets.
The all-cause death rate was 20.2% (34/168) at the time of the follow-up. Cardiac-related deaths occurred in 7.7% of patients (13/168), with heart failure, acute myocardial infarction, and cardiac arrhythmias being major causes. Noncardiac-related deaths occurred in 12.5% of patients (21/168). Cancer and infections constituted the majority of causes, but some of the deaths were due to renal failure, cerebrovascular lesion, liver cirrhosis, pulmonary embolism, and complications after femur fractures. Figure 2 shows the screening and inclusion process. A total of 97 patients were included in the clinical evaluation, and 91 patients underwent CTA. Baseline and perioperative clinical characteristics are shown in Table 1 . The patients are divided into 2 groups: no LITA harvested and LITA harvested, but the LITA was not used or it was anastomosed to non-LAD target coronaries. Patients in the no LITA harvested group were older (P ¼ .017), had a lower ejection fraction (P ¼ .029), and had higher risk scores (additive European System for Cardiac Operative Risk Evaluation score [euroSCORE] 6.63 AE 3.5 vs 4.5 AE 2.7, P ¼ .001;
and Higgins score 4.3 AE 3.5 vs 2.6 AE 2.2, P ¼ .004) compared with patients in the LITA harvested group. Patients undergoing a combined procedure consisted of 33.3% (42/126) of the no LITA harvested group versus 11.9% (5/42) of the LITA harvested group (P ¼ .007). These differences in the groups could explain the longer aortic crossclamp and extracorporeal circulation time in the no LITA harvested group.
The reasons reported by the operating surgeons for patients not receiving a LITA graft to the LAD were single factor in 30.9% of patients (52/168) and multifactorial (2-5 factors) in 69.1% of patients (116/168). The single factors given were intermediate LAD stenosis, surgical damage, low flow, subclavian stenosis, and radiation injury. The composite factors included age 75 years or more, diabetes mellitus, obesity, COPD, heart failure, and CABG plus another procedure.
Clinical Evaluation
Clinical characteristics at a mean of 6 (4-9) years are shown in Table 2 . A total of 97 patients were included in the clinical follow-up at a mean age of 75.6 AE 8.5 years. Altogether, 88.7% of patients (86/97) were free of angina postoperatively, 44 (44/86; 51.2%) of whom had New York Heart Association class I. Many of the remaining patients had comorbidities, such as joint pain, intermittent claudication, and stroke, which lowered their functional class. In our follow-up, 93.8% of patients (91/97) were receiving antiplatelet therapy and 89.7% of patients (87/97) were being treated with statins. Recurrent angina occurred postoperatively in 11.3% of patients (11/97). One patient underwent a further CABG because of stenosis in previously nongrafted coronary arteries, and 2 patients underwent percutaneous coronary intervention with stenting, 1 to the native intermediate branch (previously grafted and occluded) and 1 to an SVG anastomosed to the posterior descending artery. Eight patients presented with angina at follow-up, 5 of whom had patent SVGs. These 8 patients were referred to a cardiologist for further evaluation.
Angiographic Evaluation
The majority of patients received an NT SVG to the LAD, as a single or sequential graft, together with sequential NT SVGs to the other target coronaries (Figure 3) .
Ninety-one patients underwent CTA (baseline euro-SCORE 6.01). The total number of NT SVGs examined with CTA was 163. These were made up of 77 single, 51 double, 27 triple, and 4 quadruple sequential grafts, and 4 Y-composite grafts. Eight LITAs were used, 4 anastomosed to marginal branches, 3 anastomosed to diagonal branches, and 1 anastomosed to the distal LAD.
Patency is reported according to distal anastomoses. The total number of distal anastomoses for the NT SVGs was 286. The distribution of NT SVG and LITA patency, based on the number of distal anastomoses and target coronary arteries, is shown in Table 3 . Table E1 shows the stratification of SVG patency according to the number of years between surgery and angiographic assessment.
Total patency was 94.4% (270/286). The patency of single and sequential NT SVGs to the LAD was 98% (50/51) versus 92.5% (37/40); consequently, NT SVGs to the LAD had a total patency of 95.6% (87/91). This is comparable to the reported patency rates for LITA to the LAD (Table E2 shows some of the major trials reporting patency of LITA and SVG to the LAD). The average patency rate for LITA to the LAD, adjusting for the number of patients in each of these studies, is 94.9%. Including only those studies that span 5.0 to 6.6 years gives an average patency of 96.0%.
The NT SVGs to non-LAD and LAD targets had a total patency of 93.8% (183/195) versus 95.6% (87/91), difference À2.6% units (95% CI, À7.4 to 2.1), P ¼ .28 (Table E3) . Thus, these figures are similar and were subjected to an equivalence analysis performed with NT SVGs to the LAD (reference) and NT SVGs to non-LAD targets for comparison. The 90% CIs are all within the AE10 percentage point margin determined a priori to indicate equivalence in patency between these grafts (Figure 4 ). In particular, the lower limit formally states that an NT SVG to a non-LAD vessel is not inferior to an NT SVG to the LAD at the 95% confidence level. 21, 22 Finally, the patency of all single and all sequential NT SVGs was 94.8% (73/77) and 94.3% (197/209), respectively.
Attrition or loss to follow-up is a potential problem in longitudinal studies. A total of 168 patients received an SVG to the LAD (Figure 2) , and at the clinical evaluation there were 97 patients available. A total of 71 patients were lost for the clinical evaluation. To examine a possible effect of selection bias, age and euroSCORE were selected as factors that (1) showed few missing values (if any) at the clinical evaluation, (2) showed differences in baseline values between the 2 groups of included and not included patients, and (3) might influence graft patency. Therefore, the analysis of all available distal anastomoses was supplemented with analyses within strata of age (<71 vs !71 years) and euroSCORE ( 5 vs >5 score points). These results are shown in Table E3 , and the differences in patency from SVGs to the LAD in the strata are only marginally different compared with those of the overall comparison. Thus, age and euroSCORE, which influence attrition, do not seem to affect the patency comparison to any large extent, although the possibility of a selection bias cannot be completely excluded. The occluded SVGs were 4 single grafts, 1 totally occluded triple graft, 1 totally occluded double sequential graft, 2 partially occluded triple grafts, 2 partially occluded double sequential grafts, and 2 partially occluded Y-composite grafts. Fifteen of the 16 occluded distal anastomoses were placed to target vessels less than 2 mm in diameter. Only 1 LITA anastomosed to a marginal artery was occluded. 
DISCUSSION
The key feature of this study is that in elderly patients with multiple comorbidities, NT SVGs placed to the LAD had a high patency similar to that reported for a LITA to the LAD at a mean of 6 years postoperatively. The selection of patients was not randomized, but most of those receiving the NT vein graft to the LAD had a higher risk of unfavorable outcome in terms of patency. The excellent clinical and patency results in these patients suggest that an arterial graft may not be necessary to replace a LITA damaged during harvesting or that a LITA is always required in a patient with extensive comorbidities, particularly when the degree of LAD stenosis is 75% or less, as recently shown by Harskamp and colleagues. 23 Likewise, Goldman and colleagues 24 report a patency of approximately 87.5% for LITA to the LAD compared with 75% for conventional SVGs to the LAD at 6 years postoperatively. 24 Tatoulis and colleagues 25 report a patency rate of 97.1% for LITA to the LAD and 60.2% for conventional SVGs to the LAD at a mean of 6.3 years. In this study, we have shown a patency rate of 98% for single NT SVGs to the LAD.
A LITA to the LAD remains the gold standard in CABG 7, 26 and should be used provided that there is no contraindication to its use. 4 Nonetheless, in patients aged 75 years or more with combined comorbidities of obesity, left ventricular dysfunction, COPD, diabetes mellitus, and combined procedures in which long-term survival benefits of arterial revascularization are questionable, [27] [28] [29] the NT SVG provides an excellent alternative.
During the study period, 2003 to 2008, a LITA graft was planned in approximately 95% of patients undergoing CABG. This is similar to a previous study in which 92.4% of LITA use was reported. 30 The patients who received a planned SVG to the LAD were significantly older, with a lower ejection fraction, higher risk scores, and more combined procedures. The second important finding, in contrast to other conduits, is that the patency of the NT SVGs to LAD and non-LAD targets was similar and high. The analysis, according to Fleming 21 and Christensen, 22 shows CIs within the margins of equivalence (Figure 4 ). This indicates that the target vessel size, the vessel quality, and the degree of stenosis have little or no effect on NT SVG performance, in contrast to arterial grafts. 31 This may be due to the fact that undamaged or minimally manipulated NT SVGs anastomosed to different target vessels possess a greater ability to positively or negatively remodel, either increasing or decreasing in size according to flow demand. 32 These findings are consistent with the results of our previous, randomized study in which patency rates of NT conduits were independent of target vessel size and quality and conduit flow rates. 15 Even saphenous veins that were judged to be of a lower quality had an excellent patency rate when harvested by the NT technique.
Furthermore, there was no significant difference in the patency of single and sequential grafts. This last feature may not be due to the target vessel runoff but to the surrounding tissue that remains intact in NT grafts and acts as a biological, external stent protecting the long sequential grafts from kinking and reducing the potential for technical error. In the present study, 94.3% of the sequential anastomoses were patent.
If the NT SVG is a good alternative for the LAD, it could be considered more often as the second choice for any conduit in CABG. 33 The follow-up is not yet long term, but at 6 years the results are good. There has been an increasing promotion of extensive arterial use 7 based on patency studies. This recommendation is most reasonable given the poor quality of conventionally harvested saphenous veins. However, NT SVGs have a significantly better quality, making the recommendation less compelling.
Even if extensive arterial revascularization is performed, SVGs still account for the majority of conduits used in most centers. 34 This is due to numerous advantages of using the saphenous vein, including ease of access and manipulation, sufficient length for grafting, and short harvesting time. Clinical factors also may suggest that prolonged conduit longevity is not always the primary concern. Older age, female sex, left ventricular dysfunction, smoking, obesity, and diabetes are some of the factors that negatively affect survival. 27, 29 Consequently, the benefits of extensive arterial revascularization in CABG can be short-lived in these patients. This concept is even more important given that the age and comorbidities of the population undergoing CABG are increasing. 35 Could the results of the present study, together with our previous studies, provide useful preliminary data for a large randomized trial to compare LITA-LAD with NT SVG-LAD outcomes?
Study Limitations
This is a small observational cohort trial, which potentially exposes it to selection bias. The 71 patients who were not included in the follow-up were older and had a higher rate of some comorbidities at baseline. Our analysis of a possible selection bias where the influence of age and euroSCORE was estimated for those patients available at the clinical evaluation gives us reasons to believe that selection bias is not likely a major limitation. We agree that a higher number of patients at follow-up would have strengthened our results, especially in giving it a broader basis for generalization of the outcome, and the 20.2% death rate is a limitation in this study.
CONCLUSIONS
In elderly patients with multiple comorbidities, the NT SVG represents an encouraging alternative conduit for bypassing the LAD in CABG. The equivalent high patency, to both LAD and non-LAD targets, is an outstanding feature of the NT SVG.
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